Sir, your comments on contrast media was not clear. One, this growth that we see in the quarter 4, so was iodinated contrast media product started being a part of it or the new products that you were supposed to supply, is it? And what were your exit comme nts for FY27? So should we look at the quarter 4 number? Or was it somewhere different that we had to look at the '27 growth? The comments were not clear, if you could reiterate them please.
And then validation is the iodinated contrast media product validation or it is some other product?